Laura Strom, MD
Associate Professor, Neurology

Director, Non-Epileptic Seizure Clinic
Clinic (720) 848-2080
Print Profile
Email Profile
Photo

Gender: Female
Languages: English
Department, Section/Division: Neurology
Psychiatry

Practice Locations

Neurosciences Center - Anschutz
1635 Aurora Ct
4th Floor
Aurora, CO 80045
720-848-2080
More providers at this location

UCH - Anschutz Outpatient Pavilion
1635 Aurora Ct
Aurora, CO 80045
720-848-0000
More providers at this location

Anschutz Inpatient Pavilion 2
12505 E. 16th Ave
Aurora, CO 80045
720-848-0000
More providers at this location

Hospital Affiliation
  • University of Colorado Hospital
Center Affiliations

Specialty Information

Specialties
  • Neurology - Epilepsy (2013)
  • Neurology, Board Certification (2017)
  • ABPN certification in Epilepsy, Board Certification (2013)
Conditions & Treatments
  • Brain and Nervous System
  • Epilepsy
  • Mental Health and Behavior
Clinical Interest for Patients
I am a fellowship trained Epileptologist, specializing in the care and management of patients with non-epileptic seizures. Specialty Clinics: Non-Epileptic Seizure (NES) Clinic, Tuberous Sclerosis (TS) Clinic, Functional Neurology Clinic, Clinical Trials

Care Philosophy
I started my career thinking I would be a psychiatrist and learned to listen first, suspending disbelief. Patients often have their own solutions, and the doctor needs to help the patient discover what those solutions are. I believe the doctors role is to be a partner with the patient in their care.

Personal Interests
I am an avid knitter and knitting for charity occupies a great deal of my knitting energy. I grow my own vegetables and love container gardening, composting makes everything come full circle. In addition to preserving tomatoes, pickling cucumbers and coriander seed, I make jams and jellies. I love to be outdoors doing anything.

Volunteer Activities
I served as past chair of the physician's advisory board to the Epilepsy Foundation of Colorado. I am now seated on the Board of Directors of the Foundation. I knit for a breast prostheses organization. I am a church volunteer. I am a volunteer fund raiser for the Epilepsy Foundation.

Public Speaking
Yes
NES

Information for Referring Providers

Clinical Interests for Referring Providers
My main clinical interest is in the evaluation, diagnosis and treatment of patients with non-epileptic seizures.

Research Interest for Referring Providers
CURRENT RESEARCH SUPPORT 5/28/14-Ongoing Principal Investigator USL P261-408: An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects with Seizure Clusters Direct cost per patient: $11,698 Length of Study: Until the drug is approved 11/15/2012-Ongoing Principal Investigator USL P261-402: An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects with Seizure Clusters Direct cost per patient: $9445 Length of study: Until drug is approved 1/02/14-2015 Principal Investigator Marinus 1042-0603: A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults with Drug-Resistant Partial-Onset Seizures Followed by Long-term Open-Label Treatment Direct cost per patient: $9950 Length of study: 9 months 11/19/13-2016 Principal Investigator UCB Biosciences 1379: An Open-Label, Multicenter, Follow-Up Study to evaluate the long-term safety and efficacy of Brivaracetam used as adjunctive treatment in subjects aged 16 years or older with epilepsy Direct Cost per patient: $11,939 7/09/2013-2016 Principal Investigator UCB Biosciences 1358: A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of Brivaracetam in subjects with partial onset seizures Direct Cost per patient: $11,939 1/1/12-Ongoing Principal Investigator USL P261-401: A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intranasal Midazolam (USL261) in the Outpatient Treatment of Subjects with Seizure Clusters ARTEMIS-1: Acute Rescue Therapy in Epilepsy with Midazolam Intranasal Spray-1 Direct cost per patient: $9445 Length of study: 6 months, dependent upon first seizure cluster after randomization 3/03/11 – 6/27/12 Principal Investigator UCB SP0962 study: An Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated with Long-Term Oral Lacosamide for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects with Idiopathic Generalized Epilepsy Direct costs: $6337 (per patient for entire study) Enrollment: 1 patient Length of study: 56 weeks 7/07/11-2016 Principal Investigator Sunovion BIA-2093-304 study: Efficacy and safety of eslicarbazabine acetate (BIA 2-093) as adjunctive therapy for refractory partial seizures in a double-blind, randomized, placebo-controlled parallel-group, multicenter clinical trial Direct costs: $14344 (per patient for entire study) Enrollment: 3 patients Length of study: 41 months 3/03/11 – 01/10/12 Principal Investigator UCB SP0961, An open-label pilot study to assess the safety of oral lacosamide as adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures in subjects with idiopathic generalized epilepsy Direct costs: $7878 (per patient for entire study) Enrollment: 3 patients Length of study: 24 months 11/30/09 – 2016 Principal Investigator Sunovion, 093-050 study; Long-Term Eslicarbazepine Acetate Extension Study Direct costs: $7314 (per patient for entire study) Enrollment: 2 patients at $7314 each = $14,628 Length of study: 36 mos. 12/23/09 – 05/17/12 Principal Investigator Supernus Prosper 302 study: Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR) as Adjunctive Therapy in Subjects with Refractory Partial Epilepsy on up to Three Concomitant Antiepileptic Medications Direct costs: $5270 (per patient for entire study) Indirect costs: $1370 Enrollment: 4 patients at $5270 each = $21,080 Length of study: 14 mos. 12/10/09 – 10/14/11 Principal Investigator Supernus Prosper 301 study: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Three-Arm, Parallel Group Study to Evaluate the Efficacy and Safety of Oxcarbazepine Extended-Release (OXC XR) (1200 and 2400mg/day) as Adjunctive Therapy in Subjects with Refractory Partial Seizures due to Epilepsy on up to Three Concomitant Antiepileptic Medications Direct costs: $8620 (per patient for entire study) Indirect costs: $2241 Enrollment: 4 patients at $8620 each = $34,480 Length of study: 8-9 mos. 11/06/09 – 08/29/13 Principal Investigator Sunovion 093-045 study: Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects with Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs Direct costs: $12030 (per patient for entire study) Indirect costs: $3027 Enrollment: 3 patients at $12030 each = $36,090 Length of study: 2 yrs. 01/31/08 – 01/15/10 Principal Investigator Marinus Pharmaceuticals, Inc, Research 1042-0601 study; an open-label extension study to evaluate the safety, tolerability, and efficacy of ganaxolone as add-on therapy in adult patients with epilepsy consisting of uncontrolled partial-onset seizures. 01/31/08 – 02/25/09 Principal Investigator Marinus Pharmaceuticals, Inc, Research 1042-0600 study; A double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, and efficacy of ganaxolone as add-on therapy in adult subjects with epilepsy consisting of uncontrolled partial-onset seizures.

Clinic Phone: (720) 848-2080

CV CV Strom_2.25.2019revised.doc
Contact Us
In An Emergency: Please Dial 911

University of Colorado Medicine (CU Medicine)
http://www.CUmedicine.us/contact-us
Refer a Patient: 720-848-2828
Billing Questions: 303-493-7000

Twitter   Facebook
CU Doctors